Recent Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol’s Abilify adds bipolar maintenance indication; AstraZeneca’s Atacand receives approval for heart failure in advance of advisory committee review; other recent approvals in brief